August 20, 2024 /

Webinar: Advancing DYNE-251 – An Investigational Medicine for Duchenne to Deliver for Patients

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

Dyne Therapeutics joined PPMD for a presentation of clinical data from the DELIVER Trial of DYNE-251 in individuals living with Duchenne muscular dystrophy who are amenable to exon 51 skipping, first released on May 20th, 2024. These data demonstrated compelling impact on key disease biomarkers and trends in improvement of multiple functional endpoints.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo